Edition:
India

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

39.20USD
18 Sep 2020
Change (% chg)

$1.36 (+3.59%)
Prev Close
$37.84
Open
$38.14
Day's High
$40.20
Day's Low
$37.61
Volume
443,185
Avg. Vol
246,084
52-wk High
$76.98
52-wk Low
$24.82

Latest Key Developments (Source: Significant Developments)

Esperion To Present Final Results Of Bempedoic Acid Pivotal Phase 3 Study 2
Monday, 18 Mar 2019 

March 18 (Reuters) - Esperion Therapeutics Inc ::ESPERION ANNOUNCES LATE-BREAKING PRESENTATION OF FINAL RESULTS OF BEMPEDOIC ACID PIVOTAL PHASE 3 STUDY 2 AT THE AMERICAN COLLEGE OF CARDIOLOGY 2019 SCIENTIFIC SESSIONS.ESPERION THERAPEUTICS INC - STUDY 2 DEMONSTRATED BEMPEDOIC ACID SIGNIFICANTLY LOWERED LDL-CHOLESTEROL AND REDUCED HSCRP.ESPERION - OVER 52-WEEKS, BEMPEDOIC ACID WAS OBSERVED TO BE SAFE, WELL-TOLERATED, AND ADVERSE EVENT PROFILE WAS SIMILAR TO THAT OF PLACEBO.  Full Article

Esperion Provides Bempedoic Acid Franchise Development Program Updates, Reports Fourth Quarter Results
Friday, 1 Mar 2019 

Feb 28 (Reuters) - Esperion Therapeutics Inc ::ESPERION PROVIDES BEMPEDOIC ACID FRANCHISE DEVELOPMENT PROGRAM UPDATES; REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.ESPERION THERAPEUTICS INC - ESPERION EXPECTS 2019 NET CASH USED IN OPERATIONS TO BE $25 TO $35 MILLION.ESPERION THERAPEUTICS INC - QTRLY LOSS PER SHARE $2.24.  Full Article

BRIEF-Esperion Enters Into Amendment No. 1 To License And Collaboration Agreement With Daiichi Sankyo Europe GmbH

* ESPERION THERAPEUTICS - ENTERED INTO AMENDMENT NO. 1 TO LICENSE AND COLLABORATION AGREEMENT WITH DAIICHI SANKYO EUROPE GMBH